PROCEPT BioRobotics Corp (PRCT)
“Water is the most selective surgeon” — the design principle behind PROCEPT’s aquablation technology, which uses a narrow jet of pressurized water to ablate diseased tissue with precision while sparing surrounding structures.
PROCEPT BioRobotics is a medical-device company whose entire commercial existence rests on a single observation: the standard surgical treatments for benign prostatic hyperplasia — enlarged prostate, a common condition in aging men — are either crude and destructive or limited in application. The company’s response is a device called AquaBeam, which uses robotic control and precisely aimed water jets to vaporize excess prostate tissue with minimal trauma to surrounding nerve and muscle, offering a middle path between crude and incomplete.
The benign prostatic hyperplasia problem and the path to AquaBeam
Benign prostatic hyperplasia is epidemic in aging men. The prostate naturally enlarges with age, and in many cases the overgrowth restricts the flow of urine, causing frequency, urgency, nocturia, and a weak stream. When medications fail to help, men have historically faced urology’s version of surgical crude: a transurethral resection of prostate, or TURP, which passes a rigid instrument through the urethra and uses an electrical loop to scrape away the excess tissue. TURP is effective but destructive — it can cause erectile dysfunction, incontinence, and retrograde ejaculation, and it has a ceiling on how much tissue can safely be removed in one session, limiting its usefulness in very large prostates.
PROCEPT’s founders reasoned that water — a jet of pressurized saline delivered with enough force to vaporize tissue but controlled precisely enough to avoid collateral damage — could do the same job more selectivity. The result was AquaBeam, a robot-guided system where a surgeon sits at a console, visualizes the prostate on ultrasound, traces the tissue to be removed, and the robot delivers water jets along that path. The water vaporizes the targeted tissue layer by layer while the jet’s pressure stays below the threshold that would harm the surrounding capsule or penetrate deep enough to damage the urinary sphincter or nerves.
The clinical advantage is substantial: patients undergoing AquaBeam show durable symptom improvement with lower rates of the sexual and continence side effects that plague TURP, and the technology can be used on very large prostates that would be risky to treat with TURP alone. For urologists, it offers a new tool in a market where alternatives are limited and largely unchanged in decades.
Market and adoption dynamics
Benign prostatic hyperplasia is common enough that millions of men seek treatment annually in the United States and developed markets worldwide. Yet the market for new surgical approaches in BPH has historically been underserved. Urologists are trained on TURP and medications, and inertia runs deep. PROCEPT’s path to adoption has required not just convincing hospital systems to buy a new piece of capital equipment — a capital robotic system carries significant cost — but also convincing surgeons to invest time in learning it and hospital administrators that the economic equation works: the improved patient outcomes and reduced complications justify the capital spending and the training curve.
The company’s go-to-market strategy has centered on teaching hospitals and urology centers where innovation adoption is most likely, combined with clinical data showing safety and efficacy. Early studies and real-world experience have built a body of evidence supporting AquaBeam’s advantages, and the installed base has grown. Growth remains challenging — adoption of new surgical techniques is a multi-year process — but the total addressable market in BPH is vast, and PROCEPT owns a novel technology with meaningful clinical differentiation.
Competition and the therapeutic landscape
PROCEPT’s advantage is not unique but is meaningful. Surgical alternatives for BPH include TURP, bipolar TURP (slightly newer), laser enucleation (which some surgeons favor), and urethral stents (for high-risk patients). Medications like alpha-blockers and 5-alpha-reductase inhibitors remain first-line for many. PROCEPT competes primarily against the surgical status quo — TURP and its variants — rather than against a specific competitor’s device, though there are other robotic or energy-based approaches in development or early adoption.
The competitive moat is the patent protection around the aquablation technology, the clinical evidence supporting it, and the installed base of urologists trained and invested in using it. As more surgeons learn the technique and hospital systems deploy the platform, switching costs rise. A surgeon who has trained extensively on AquaBeam is unlikely to switch unless a clearly superior technology emerges.
The business model and path to scale
PROCEPT is a pure-play medical-device company with recurring revenue. The company sells the AquaBeam systems themselves — a capital equipment sale to hospitals and surgery centers — and generates ongoing revenue from disposable consumables (the sterile, single-use kits required for each procedure) and service contracts. The recurring revenue from consumables is the strategic engine: once a center buys the robot, it must buy kits for every case, creating a predictable revenue stream with healthy margins.
The economics of medical-device businesses at scale are well-established: high gross margins on both systems and consumables, large upfront capital and R&D requirements, and a long sales cycle before a new product reaches meaningful revenue. PROCEPT’s burn rate and path to profitability depend on how quickly installation of systems ramps and whether the company can drive procedure volume per system toward the target capacity that justifies the capital investment.
Regulatory and reimbursement factors
AquaBeam operates in the heavily regulated medical-device space, requiring approval from the FDA and clearance in international markets. The company has obtained FDA clearance in the United States and marketing authorization in other countries, de-risking the fundamental regulatory question. Beyond approval, however, reimbursement is critical: hospitals and surgery centers buy devices that insurance and government programs will pay for. If Medicare, commercial insurers, and international health systems view aquablation favorably and reimburse it at rates comparable to TURP, adoption accelerates. If reimbursement lags or is restricted, growth stalls.
PROCEPT’s opportunity and its risks both center on adoption speed and reimbursement certainty. The addressable market is large and the technology is differentiated, but scaling a surgical innovation requires sustained investment, durable clinical outcomes, and payer cooperation. For investors, watching the quarterly procedure volume per system, the total installed base, and commentary on reimbursement trends from earnings calls reveals whether the company is on track to become a significant player in urology or faces headwinds to scale.